Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
Clin Gastroenterol Hepatol ; 21(4): 1108-1110.e1, 2023 04.
Artigo em Inglês | MEDLINE | ID: mdl-35227889

RESUMO

Eosinophilic esophagitis (EoE) is a chronic immune-mediated disorder characterized by esophageal inflammation and dysfunction, with a rising incidence affecting approximately 1:1000 individuals worldwide.1,2 Chronic inflammation can lead to tissue remodeling in the esophagus with fibrosis in the lamina propria that is partially responsible for symptoms and complications of EoE.3,4 At times, a firmness to the esophagus can be appreciated with a noticeable force required to obtain biopsies from EoE. This sensation has been described as the "tug" or "pull" sign.5,6 Recently, with the advent of endoscopic functional luminal impedance, the fibroelastic properties of the esophagus, including diminished compliance and distensibility, have been described in patients with EoE.7 Quantification of these fibroelastic properties of the esophagus may aid in diagnosis and prognosis of EoE. To this date, a method to quantitatively measure the "tug sign" has not been developed. The primary objective of this study was to measure if a quantifiable difference in force is required to obtain endoscopic esophageal biopsies in patients with EoE compared with those without.


Assuntos
Esofagite Eosinofílica , Humanos , Esofagite Eosinofílica/patologia , Esofagoscopia , Biópsia , Inflamação
2.
Ann Vasc Surg ; 87: 100-112, 2022 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-35398194

RESUMO

BACKGROUND: An infection-resistant, immediately available conduit for trauma and urgent vascular reconstruction remains a critical need for successful limb salvage. While autologous vein remains the gold standard, vein-limited patients and size mismatch are common issues. The Human Acellular Vessel (HAV) (Humacyte, Inc., Durham, NC) is a bioengineered conduit with off-the-shelf availability and resistance to infection, ideal characteristics for patients with challenging revascularization scenarios. This report describes HAV implantation in patients with complex limb-threatening ischemia and limited conduit options who may have otherwise faced limb loss. METHODS: The Food and Drug Administration (FDA) expanded-access program was used to allow urgent implantation of the HAV for arterial reconstruction. Electronic medical records were reviewed with extraction of relevant data including patient demographics, surgical implantation, patency, infectious complications, and mortality. RESULTS: The HAV was implanted in 8 patients requiring vascular reconstruction. Graft or soft tissue infection was present in 2 patients. One patient with severe penetrating pelvic injury had 4 HAV placed to repair bilateral external iliac artery and vein injuries. There was 1 technical failure due to poor outflow, 2 patients died unrelated to HAV use, and 5 lower extremity bypasses maintained patency at an average of 11.4 months (range: 4-20 months). No HAV infectious complications were identified. CONCLUSIONS: This report is the first United States series describing early outcomes using the HAV under the FDA expanded-access program for urgent vascular reconstruction. The HAV demonstrates resistance to infection, reliable patency, and offers surgeons an immediate option when confronted with complex revascularization scenarios. Assessment of long-term outcomes will be important for future studies.


Assuntos
Arteriopatias Oclusivas , Implante de Prótese Vascular , Doenças Vasculares Periféricas , Humanos , Implante de Prótese Vascular/efeitos adversos , Resultado do Tratamento , Salvamento de Membro , Isquemia/diagnóstico por imagem , Isquemia/cirurgia , Extremidade Inferior/irrigação sanguínea , Arteriopatias Oclusivas/cirurgia , Doenças Vasculares Periféricas/cirurgia , Grau de Desobstrução Vascular , Estudos Retrospectivos , Prótese Vascular
3.
BMJ Case Rep ; 14(11)2021 Nov 30.
Artigo em Inglês | MEDLINE | ID: mdl-34848428

RESUMO

A pituitary abscess is a rare intrasellar infection. Correct identification can be challenging preoperatively given its non-specific symptoms and imaging findings. We report a case of a young woman presenting with secondary amenorrhea, visual field deficits and a 2.6 cm pituitary lesion diagnosed to be a craniopharyngioma. A concomitant unexpected pituitary abscess was diagnosed intraoperatively without associated meningeal symptoms.


Assuntos
Abscesso Encefálico , Craniofaringioma , Doenças da Hipófise , Neoplasias Hipofisárias , Abscesso Encefálico/diagnóstico por imagem , Abscesso Encefálico/cirurgia , Craniofaringioma/diagnóstico , Craniofaringioma/diagnóstico por imagem , Feminino , Humanos , Imageamento por Ressonância Magnética , Doenças da Hipófise/diagnóstico , Neoplasias Hipofisárias/diagnóstico , Neoplasias Hipofisárias/diagnóstico por imagem
4.
Infect Control Hosp Epidemiol ; 41(4): 404-410, 2020 04.
Artigo em Inglês | MEDLINE | ID: mdl-32052726

RESUMO

OBJECTIVE: To evaluate the National Health Safety Network (NHSN) hospital-onset Clostridioides difficile infection (HO-CDI) standardized infection ratio (SIR) risk adjustment for general acute-care hospitals with large numbers of intensive care unit (ICU), oncology unit, and hematopoietic cell transplant (HCT) patients. DESIGN: Retrospective cohort study. SETTING: Eight tertiary-care referral general hospitals in California. METHODS: We used FY 2016 data and the published 2015 rebaseline NHSN HO-CDI SIR. We compared facility-wide inpatient HO-CDI events and SIRs, with and without ICU data, oncology and/or HCT unit data, and ICU bed adjustment. RESULTS: For these hospitals, the median unmodified HO-CDI SIR was 1.24 (interquartile range [IQR], 1.15-1.34); 7 hospitals qualified for the highest ICU bed adjustment; 1 hospital received the second highest ICU bed adjustment; and all had oncology-HCT units with no additional adjustment per the NHSN. Removal of ICU data and the ICU bed adjustment decreased HO-CDI events (median, -25%; IQR, -20% to -29%) but increased the SIR at all hospitals (median, 104%; IQR, 90%-105%). Removal of oncology-HCT unit data decreased HO-CDI events (median, -15%; IQR, -14% to -21%) and decreased the SIR at all hospitals (median, -8%; IQR, -4% to -11%). CONCLUSIONS: For tertiary-care referral hospitals with specialized ICUs and a large number of ICU beds, the ICU bed adjustor functions as a global adjustment in the SIR calculation, accounting for the increased complexity of patients in ICUs and non-ICUs at these facilities. However, the SIR decrease with removal of oncology and HCT unit data, even with the ICU bed adjustment, suggests that an additional adjustment should be considered for oncology and HCT units within general hospitals, perhaps similar to what is done for ICU beds in the current SIR.


Assuntos
Infecções por Clostridium/epidemiologia , Infecção Hospitalar/epidemiologia , Infecção Hospitalar/microbiologia , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Unidades de Terapia Intensiva/estatística & dados numéricos , Serviço Hospitalar de Oncologia/estatística & dados numéricos , Centros Médicos Acadêmicos , California/epidemiologia , Clostridioides difficile , Infecções por Clostridium/prevenção & controle , Infecção Hospitalar/prevenção & controle , Instalações de Saúde , Células-Tronco Hematopoéticas , Hospitais Gerais , Humanos , Estudos Retrospectivos , Risco Ajustado , Segurança , Centros de Atenção Terciária , Transplantes
5.
Am J Infect Control ; 47(3): 305-312, 2019 03.
Artigo em Inglês | MEDLINE | ID: mdl-30333081

RESUMO

BACKGROUND: Increases in liver transplant patient perioperative acuity have resulted in frail immunosuppressed patients at elevated risk for nosocomial infections. Avoiding central line-associated bloodstream infections (CLABSIs) is paramount to facilitate transplantation and post-transplant recovery. In 2015, our liver transplant intensive care unit (ICU) CLABSIs accounted for more than 25% of all CLABSI at our institution. We therefore undertook a multidisciplinary collaborative among clinical epidemiology, nursing, transplant surgery, and critical care to eliminate CLABSI events. METHODS: From 2014-2016, using Lean methodology and plan-do-study-act (PDSA) cycles, 14 interventions were implemented in the liver transplant ICU. Interventions were aimed at infection prevention, care standardization, and team-based monitoring. Implementation used quality improvement methodology including audit and feedback, education, standardization, multidisciplinary stakeholder involvement, and PDSA cycles. Process measures were monitored and audited. CLABSI rates per 1,000 central venous catheter (CVC) days were tracked by clinical epidemiology. RESULTS: During the intervention, 901 CVC catheter audits were completed. Improvements were seen on all process measures, and complete compliance increased from 25%-67%. CLABSI infection rates dropped from 4.2 to 1.8 in 1,000 CVC days, with an average of less than 1 CLABSI per month. This marked a 61.2% annual reduction, which correlated with an estimated $935,000 annual savings. CONCLUSION: Concerted ongoing multidisciplinary collaboratives are essential to minimize CLABSI and optimize value and quality in a challenging, high-acuity patient population.


Assuntos
Infecções Relacionadas a Cateter/epidemiologia , Infecções Relacionadas a Cateter/prevenção & controle , Cateterismo Venoso Central/efeitos adversos , Controle de Infecções/métodos , Controle de Infecções/organização & administração , Sepse/epidemiologia , Sepse/prevenção & controle , Humanos , Unidades de Terapia Intensiva , Transplante de Fígado
6.
Infect Control Hosp Epidemiol ; 37(11): 1323-1330, 2016 11.
Artigo em Inglês | MEDLINE | ID: mdl-27457254

RESUMO

OBJECTIVE To evaluate the impact of discontinuation of contact precautions (CP) for methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) and expansion of chlorhexidine gluconate (CHG) use on the health system. DESIGN Retrospective, nonrandomized, observational, quasi-experimental study. SETTING Two California hospitals. PARTICIPANTS Inpatients. METHODS We compared hospital-wide laboratory-identified clinical culture rates (as a marker of healthcare-associated infections) 1 year before and after routine CP for endemic MRSA and VRE were discontinued and CHG bathing was expanded to all units. Culture data from patients and cost data on material utilization were collected. Nursing time spent donning personal protective equipment was assessed and quantified using time-driven activity-based costing. RESULTS Average positive culture rates before and after discontinuing CP were 0.40 and 0.32 cultures/100 admissions for MRSA (P=.09), and 0.48 and 0.40 cultures/100 admissions for VRE (P=.14). When combining isolation gown and CHG costs, the health system saved $643,776 in 1 year. Before the change, 28.5% intensive care unit and 19% medicine/surgery beds were on CP for MRSA/VRE. On the basis of average room entries and donning time, estimated nursing time spent donning personal protective equipment for MRSA/VRE before the change was 45,277 hours/year (estimated cost, $4.6 million). CONCLUSION Discontinuing routine CP for endemic MRSA and VRE did not result in increased rates of MRSA or VRE after 1 year. With cost savings on materials, decreased healthcare worker time, and no concomitant increase in possible infections, elimination of routine CP may add substantial value to inpatient care delivery. Infect Control Hosp Epidemiol 2016;1-8.


Assuntos
Infecção Hospitalar , Infecções por Bactérias Gram-Positivas/epidemiologia , Infecções por Bactérias Gram-Positivas/prevenção & controle , Custos Hospitalares , Controle de Infecções/economia , Controle de Infecções/métodos , Centros Médicos Acadêmicos , Anti-Infecciosos Locais/economia , Anti-Infecciosos Locais/uso terapêutico , California/epidemiologia , Clorexidina/análogos & derivados , Clorexidina/economia , Clorexidina/uso terapêutico , Infecção Hospitalar/economia , Infecção Hospitalar/epidemiologia , Infecção Hospitalar/prevenção & controle , Doenças Endêmicas/economia , Doenças Endêmicas/prevenção & controle , Higiene das Mãos/economia , Humanos , Staphylococcus aureus Resistente à Meticilina/isolamento & purificação , Roupa de Proteção/economia , Análise de Regressão , Estudos Retrospectivos , Infecções Estafilocócicas/prevenção & controle , Enterococos Resistentes à Vancomicina/isolamento & purificação
7.
Gastrointest Endosc ; 83(6): 1121-9, 2016 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-26993149

RESUMO

BACKGROUND AND AIMS: The duodenoscopes used to perform ERCP have been implicated in several outbreaks of carbapenem-resistant Enterobacteriaceae (CRE) infection. The risk factors for CRE transmission via contaminated duodenoscopes remain unclear. METHODS: In this retrospective, single-center, case-control study, all patients who underwent ERCP with either 1 of 2 contaminated duodenoscopes were evaluated. We compared the patients who acquired CRE (active infection or colonization) with those who did not. RESULTS: Between October 3, 2014, and January 28, 2015, a total of 125 procedures were performed on 115 patients by using either of the contaminated duodenoscopes. Culture data were available for 104 of the 115 exposed patients (90.4%). Among these patients, 15 (14.4%) became actively infected (n = 8, 7.7%) or colonized (n = 7, 6.7%) with CRE. On univariate analysis, recent antibiotic exposure (66.7% vs 37.1%; P = .046), active inpatient status (60.0% vs 28.1%; P = .034), and a history of cholangiocarcinoma (26.7% vs 3.4%; P = .008) were patient characteristics associated with an increased risk of CRE infection. Biliary stent placement (53.3% vs 22.5%; P = .024) during ERCP was a significant procedure-related risk factor. After adjusting for cholangiocarcinoma, biliary stent placement (odds ratio 3.62; 95% confidence interval, 1.12-11.67), and active inpatient status (odds ratio 3.74; 95% confidence interval, 1.15-12.12) remained independent risk factors for CRE transmission. CONCLUSIONS: In patients undergoing ERCP with a contaminated duodenoscope, biliary stent placement, a diagnosis of cholangiocarcinoma, and active inpatient status are associated with an increased risk of CRE transmission.


Assuntos
Carbapenêmicos , Portador Sadio/epidemiologia , Colangiopancreatografia Retrógrada Endoscópica/efeitos adversos , Duodenoscópios/microbiologia , Contaminação de Equipamentos , Infecções por Klebsiella/epidemiologia , Klebsiella pneumoniae/isolamento & purificação , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/uso terapêutico , Neoplasias dos Ductos Biliares/epidemiologia , Estudos de Casos e Controles , Criança , Colangiocarcinoma/epidemiologia , Farmacorresistência Bacteriana/genética , Enterobacteriaceae/genética , Enterobacteriaceae/isolamento & purificação , Infecções por Enterobacteriaceae/epidemiologia , Infecções por Enterobacteriaceae/etiologia , Feminino , Hospitalização/estatística & dados numéricos , Humanos , Infecções por Klebsiella/etiologia , Klebsiella pneumoniae/genética , Masculino , Pessoa de Meia-Idade , Razão de Chances , Estudos Retrospectivos , Fatores de Risco , Stents/estatística & dados numéricos , Adulto Jovem
8.
Infect Control Hosp Epidemiol ; 37(1): 36-40, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26486272

RESUMO

BACKGROUND Studies have suggested that contact precautions (CP) for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus may have risks that outweigh the benefits. These risks, coupled with more widespread use of horizontal interventions such as daily bathing with chlorhexidine gluconate, have brought into question the value of routine CP for these organisms. OBJECTIVE To assess the state of utilization of CP as well as adjunctive measures to reduce the risk of transmission in US hospitals. DESIGN Cross-sectional survey. PARTICIPANTS Total of 751 physician members of the Emerging Infections Network. METHODS An 8-question electronic survey distributed by email. RESULTS A total of 426/751 (57%) responded to the survey; 337/364 (93%) of respondents use routine CP for methicillin-resistant S. aureus and 335/364 (92%) use routine CP for vancomycin-resistant enterococcus. The most widely used trigger for initiation of CP for both pathogens was positive clinical culture. Practices for discontinuation of isolation varied widely. We found that 325/354 (92%) perform routine chlorhexidine gluconate bathing and 236/353 (67%) perform S. aureus decolonization with mupirocin for 1 or more subsets of inpatients, and 82/356 (23%) reported using either hydrogen peroxide vapor or ultraviolet-C room disinfection at discharge. Free text responses noted frustration and variation in the application, practice, and process for initiation and discontinuation of CP. CONCLUSIONS Use of CP for methicillin-resistant S. aureus and vancomycin-resistant enterococcus remains commonplace, although horizontal interventions such as chlorhexidine gluconate bathing are increasingly used. The heterogeneity of practices and policies was striking. Evidence-based guidelines regarding CP and horizontal interventions are needed. Infect. Control Hosp. Epidemiol. 2015;37(1):36-40.


Assuntos
Infecções por Bactérias Gram-Positivas/prevenção & controle , Staphylococcus aureus Resistente à Meticilina , Isolamento de Pacientes/métodos , Infecções Estafilocócicas/prevenção & controle , Enterococos Resistentes à Vancomicina , Antibacterianos/uso terapêutico , Anti-Infecciosos Locais/uso terapêutico , Banhos/estatística & dados numéricos , Clorexidina/análogos & derivados , Clorexidina/uso terapêutico , Estudos Transversais , Desinfecção/métodos , Humanos , Peróxido de Hidrogênio , Staphylococcus aureus Resistente à Meticilina/isolamento & purificação , Mupirocina/uso terapêutico , Quartos de Pacientes , Inquéritos e Questionários , Raios Ultravioleta , Estados Unidos , Enterococos Resistentes à Vancomicina/isolamento & purificação
11.
Cancer Causes Control ; 24(11): 1901-9, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-23901020

RESUMO

BACKGROUND: Increasing evidence suggests that oral microbiota play a pivotal role in chronic diseases, in addition to the well-established role in periodontal disease. Moreover, recent studies suggest that oral bacteria may also be involved in carcinogenesis; periodontal disease has been linked to several cancers. In this study, we examined whether lifestyle factors have an impact on antibody levels to oral bacteria. METHODS: Data on demographic characteristics, lifestyle factors, and medical conditions were obtained at the time of blood sample collection. For the current analysis, we measured antibody levels to 25 oral bacteria in 395 cancer-free individuals using an immunoblot array. Combined total immunoglobin G (IgG) levels were obtained by summing concentrations for all oral bacteria measured. RESULTS: IgG antibody levels were substantially lower among current and former smokers (1,697 and 1,677 ng/mL, respectively) than never smokers (1,960 ng/mL; p trend = 0.01), but did not vary by other factors, including body mass index, diabetes, physical activity, or by dietary factors, after adjusting for age, sex, education, country, and smoking status. The highest levels of total IgG were found among individuals with low education (2,419 ng/mL). CONCLUSIONS: Our findings on smoking are consistent with previous studies and support the notion that smokers have a compromised humoral immune response. Moreover, other major factors known to be associated with inflammatory markers, including obesity, were not associated with antibody levels to a large number of oral bacteria.


Assuntos
Anticorpos Antibacterianos/metabolismo , Bactérias/crescimento & desenvolvimento , Dieta , Estilo de Vida , Fumar , Idoso , Anticorpos Antibacterianos/imunologia , Bactérias/classificação , Bactérias/imunologia , Western Blotting , Índice de Massa Corporal , Estudos de Coortes , Diabetes Mellitus/imunologia , Diabetes Mellitus/metabolismo , Escolaridade , Europa (Continente) , Feminino , Interações Hospedeiro-Patógeno/imunologia , Humanos , Imunoglobulina G/imunologia , Imunoglobulina G/metabolismo , Modelos Lineares , Masculino , Microbiota , Pessoa de Meia-Idade , Boca/microbiologia , Neoplasias/imunologia , Neoplasias/metabolismo , População Branca
12.
J Clin Microbiol ; 51(3): 869-73, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23269736

RESUMO

Many clinical laboratories in the United States are transitioning from toxin enzyme immunoassays (EIA) to nucleic acid amplification tests (NAATs) as the primary diagnostic test for Clostridium difficile infection (CDI). While it is known that the analytical sensitivity of the toxin EIA is poor, there are limited clinical data on the performance of these assays for patients with mild or severe CDI. Two hundred ninety-six hospital inpatients with diarrhea and clinical suspicion for CDI were tested prospectively by toxin EIA, by C. difficile NAAT, and with a reference standard toxigenic culture. Following completion of laboratory testing, retrospective chart reviews were performed to stratify patients into mild and severe disease groups based on clinical criteria using a standard point-based system. One hundred forty-three patients with CDI confirmed by toxigenic culture were evaluated in this study. Among the patients with mild CDI, 49% tested positive by toxin EIA and 98% tested positive by NAAT. Among patients with severe CDI, 58% tested positive by toxin EIA and 98% tested positive by NAAT. Increased CDI disease severity was not associated with an increased sensitivity of EIA (P = 0.31). These data demonstrate that toxin EIA performs poorly both for patients with severe CDI and for those with mild CDI and support the routine use of NAAT for the diagnosis of CDI. The presence of stool toxin measured by EIA does not correlate with disease severity.


Assuntos
Toxinas Bacterianas/isolamento & purificação , Técnicas Bacteriológicas/métodos , Clostridioides difficile/isolamento & purificação , Infecções por Clostridium/diagnóstico , Testes Diagnósticos de Rotina/métodos , Técnicas de Amplificação de Ácido Nucleico/métodos , Adulto , Idoso , Idoso de 80 Anos ou mais , Toxinas Bacterianas/genética , Toxinas Bacterianas/imunologia , Clostridioides difficile/genética , Clostridioides difficile/imunologia , Infecções por Clostridium/microbiologia , Infecções por Clostridium/patologia , Diarreia/diagnóstico , Diarreia/microbiologia , Diarreia/patologia , Feminino , Humanos , Técnicas Imunoenzimáticas/métodos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Sensibilidade e Especificidade , Índice de Gravidade de Doença , Estados Unidos
13.
Semin Oncol ; 31(2 Suppl 4): 91-8, 2004 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15124141

RESUMO

Fungal infections continue to plague patients undergoing treatment of malignancies. In fact, the incidence as well as the types of fungal species causing serious invasive fungal infections is increasing. Candida infections have become the fourth leading cause of nosocomial blood stream infections. Moreover, in addition to Aspergillus, non-Aspergillus species have emerged as etiologic agents of mold infections in cancer patients. Recently, there have been new and much needed re-enforcements to the antifungal armamentarium. These include the broader triazole antifungal agents that are in clinical trials (posaconazole) or have been recently approved (voriconazole) and the echinocandins, a new antifungal class of which the first approved agent caspofungin is now available. We review the clinical data, side effects, drug interactions, and unique spectrum of activity of these newer antifungal agents against both Candida and clinically relevant mold species.


Assuntos
Antifúngicos/uso terapêutico , Micoses/tratamento farmacológico , Neoplasias/microbiologia , Infecções Oportunistas/tratamento farmacológico , Peptídeos Cíclicos , Adulto , Aspergilose/tratamento farmacológico , Candidíase/tratamento farmacológico , Caspofungina , Equinocandinas , Feminino , Fungemia/tratamento farmacológico , Humanos , Hospedeiro Imunocomprometido , Lipopeptídeos , Masculino , Pessoa de Meia-Idade , Micetoma/tratamento farmacológico , Neoplasias/imunologia , Peptídeos/uso terapêutico , Pirimidinas/uso terapêutico , Scedosporium , Triazóis/uso terapêutico , Voriconazol
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA